Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12221422
APP PUB NO 20220274932A1
SERIAL NO

17699408

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to oxopyrimidinyl-methyl-benzamide derivatives, for example in a pharmaceutically acceptable salt form or crystal form, pharmaceutical compositions comprising the derivatives, and their medical use, in particular for use in the treatment of α1-antitrypsin deficiency (A1AD or AATD).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • CENTESSA PHARMACEUTICALS (UK) LIMITED

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fox, David John Coventry, GB 27 17
Huntington, James Andrew Babraham, GB 21 33
Ramsden, Nigel Babraham, GB 34 263

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Aug 11, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 11, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 11, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00